Rescue Pharmacotherapy for OSA
Public ClinicalTrials.gov record NCT05293600. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Treating Residual OSA With Endotype-directed Pharmacotherapy (Aim 3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Persistent obstructive sleep apnea (OSA) is common in people treated with mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). For most patients, these treatments are the last line of defense. If MAD or HGNS do not work, then patients are left to suffer the consequences of undertreated OSA. In this study, the investigators want to test the addition of a drug treatment to their regimen. Endotypes will be targeted pharmacologically with one of the following drugs: acetazolamide for a high loop gain, atomoxetine-plus-eszopiclone for poor pharyngeal muscle compensation, or trazodone for a low arousal threshold. This aim is expected to provide treatment strategies for rescuing non-responders to MAD or HGNS therapy.
Study identification
- NCT ID
- NCT05293600
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2023
- Primary completion
- Oct 29, 2026
- Completion
- Oct 29, 2026
- Last update posted
- Jul 14, 2026
2023 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sleep Disorders Research Program Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Obstructive Sleep Apnea trials
Other public records listing Obstructive Sleep Apnea. Sorted by last update posted; newest first. Not a recommendation.
- NCT07724938: Combination Tonsillectomy and Hypoglossal Nerve Stimulation for OSA Patients With Lateral Pharyngeal Collapse Not yet recruiting
- NCT06390345: Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention Recruiting
- NCT07301125: Myofunctional Therapy for Obstructive Sleep Apnea Recruiting
- NCT05350215: Atomoxetine and DAW2022 on OSA Severity Recruiting
- NCT06258837: Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Small Tonsils Recruiting
- NCT05953610: Endotypic Traits and Obstructive Sleep Apnea Surgery Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05293600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2026 · Synced Jul 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05293600 live on ClinicalTrials.gov.